CA3265602A1 - Aerosolisable formulation - Google Patents
Aerosolisable formulationInfo
- Publication number
- CA3265602A1 CA3265602A1 CA3265602A CA3265602A CA3265602A1 CA 3265602 A1 CA3265602 A1 CA 3265602A1 CA 3265602 A CA3265602 A CA 3265602A CA 3265602 A CA3265602 A CA 3265602A CA 3265602 A1 CA3265602 A1 CA 3265602A1
- Authority
- CA
- Canada
- Prior art keywords
- aerosolisable formulation
- aerosolisable
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2213663.4A GB202213663D0 (en) | 2022-09-16 | 2022-09-16 | Aerosolisable formulation |
| PCT/IB2023/059132 WO2024057248A1 (en) | 2022-09-16 | 2023-09-14 | Aerosolisable formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3265602A1 true CA3265602A1 (en) | 2024-03-21 |
Family
ID=84817780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3265602A Pending CA3265602A1 (en) | 2022-09-16 | 2023-09-14 | Aerosolisable formulation |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4586832A1 (en) |
| AR (1) | AR130481A1 (en) |
| CA (1) | CA3265602A1 (en) |
| GB (1) | GB202213663D0 (en) |
| TW (1) | TW202412648A (en) |
| WO (1) | WO2024057248A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150013695A1 (en) * | 2013-07-10 | 2015-01-15 | Ahkeo Ventures LLC | Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same |
| MX2023001475A (en) * | 2020-09-03 | 2023-03-08 | Rai Strategic Holdings Inc | Aerosolisable formulation. |
-
2022
- 2022-09-16 GB GBGB2213663.4A patent/GB202213663D0/en not_active Ceased
-
2023
- 2023-09-14 CA CA3265602A patent/CA3265602A1/en active Pending
- 2023-09-14 EP EP23777037.5A patent/EP4586832A1/en active Pending
- 2023-09-14 TW TW112135105A patent/TW202412648A/en unknown
- 2023-09-14 AR ARP230102441A patent/AR130481A1/en unknown
- 2023-09-14 WO PCT/IB2023/059132 patent/WO2024057248A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AR130481A1 (en) | 2024-12-11 |
| EP4586832A1 (en) | 2025-07-23 |
| GB202213663D0 (en) | 2022-11-02 |
| TW202412648A (en) | 2024-04-01 |
| WO2024057248A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202007546D0 (en) | Formulation | |
| IL319149A (en) | Upadacitinib formulation | |
| IL307849A (en) | Sotorasib formulation | |
| GB202102636D0 (en) | Formulation | |
| IL324083A (en) | Maropitant formulation | |
| GB202318884D0 (en) | Formulation | |
| GB202316857D0 (en) | Cannabinoid-based formulation | |
| CA3265602A1 (en) | Aerosolisable formulation | |
| GB202312814D0 (en) | Formulation | |
| GB202312220D0 (en) | Formulation | |
| CA3261750A1 (en) | Formulation | |
| GB202311622D0 (en) | Formulation | |
| GB202311439D0 (en) | Formulation | |
| IL317857A (en) | Orellanine formulation | |
| CA3260064A1 (en) | Aerosolisable formulation | |
| GB202308224D0 (en) | Formulation | |
| CA3251279A1 (en) | Formaldehyde-scavenging formulation | |
| GB202307002D0 (en) | Cannabinoid-based formulation | |
| GB202307003D0 (en) | Cannabinoid-based formulation | |
| GB202306990D0 (en) | Cannabinoid-based formulation | |
| GB202306995D0 (en) | Cannabinoid-based formulation | |
| GB202303663D0 (en) | Aerosolisable formulation | |
| GB202218160D0 (en) | Formulation | |
| GB202217857D0 (en) | Formulation | |
| GB202217267D0 (en) | Aerosolisable formulation |